However, many pre-clinical studies have highlighted the potential for such therapies, and a number of clinical trials are currently evaluating safety and efficacy of anti-IL-6/IL-11/STAT3 agents for the treatment of breast cancer. This evidence concerns the gene STAT3 and breast carcinoma.